ORPHAZYME

Welcome to the Brand page for “ORPHAZYME”, which is offered here for Pharmaceutical and medical preparations for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and parkinson's disease, for the treatment of amyotrophic lateral sclerosis (als), motor neuron disease (mnd) and lysosomal storage diseases (lsd) and for the treatment of niemann-pick disease type c, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; chemical-pharmaceutical preparations for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and parkinson's disease, for the treatment of amyotrophic lateral sclerosis (als), motor neuron disease (mnd) and lysosomal storage diseases (lsd) and for the treatment of niemann-pick disease type c, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; diagnostic preparations for medical purposes; reagents for medical purposes and for research; preparations for analysis for medical and research purposes for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and parkinson's disease, for the treatment of amyotrophic lateral sclerosis (als), motor neuron disease (mnd) and lysosomal storage diseases (lsd) and for the treatment of niemann-pick disease type c, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; all of the aforementioned with the exclusion of veterinary preparations and ingredients, supplements for food, and medicated foodstuffs for animals;chemicals used in industry and in science; proteins for use in science and in manufacture; biochemicals, polypeptides for scientific, research and commercial use; with the exclusion of chemicals used in the food industry and animal food industry and ingredients for foodstuffs for animals;industrial analysis and research services; basic research and clinical research, hereunder for medicine and vaccine development; all the aforementioned services with the exclusion of services relating to the veterinary sector;.

Its status is currently believed to be active. Its class is unavailable. “ORPHAZYME” is believed to be currently owned by “Orphazyme ApS”.